Team

In the summer of 2004, Rafaat founded Lifescience Dynamics. He had a vision of what would make an effective global decision support service, dedicated exclusively to pharmaceutical and biotechnology industries. It would have to be the best in class market research, competitive intelligence and market access, combined with first-rate people and a business model that met their clients’ global insight and foresight requirements. Lifescience Dynamics is privileged to boast an extraordinary worldwide customer base, with teams across the globe supporting firms of all sizes, from top 20 pharmaceutical companies through to smaller niche pharma and biotech firms. Rafaat prides himself in his dedication to his clients: “Revenue is important, but customer experience is even more crucial” is a motto reflected in everything the company does.

Prior to founding Lifescience Dynamics, Rafaat was Vice President of a London-based consulting practice where he was responsible for numerous international projects for top 10 pharmaceutical companies, focusing on all aspects of the clinical development and commercialisation environments at US, European and global levels. He has advanced knowledge of competitive intelligence, qualitative and quantitative market research techniques, market access, pricing and reimbursements. He has also previously worked for Eli Lilly & Company, Pepsi-Cola and McDonald’s in a management training programme.

Rafaat has a truly international background. He was born in India, brought up in Oman/UAE, gained a business degree in the USA and an MBA from Manchester Business School in the UK. As well as the UK, he has worked in the USA, India, Abu Dhabi and Dubai. He belongs to a large, traditional close-knit Indian family with strong family ethics and values of honesty and hard work. He says: “I was told from childhood and have always believed that it’s not just what you do but how you do it that’s important.”

Alfred Reszka, PhD joined Lifescience Dynamics in 2019 as Chief Business Officer. Al came with over 22 years of experience at Merck & Co., Inc., most recently serving 12 years in their Global Competitive Intelligence department. Al played a pivotal role in building and developing a world-class global competitive intelligence group with high impact on brand and corporate strategy. As an executive manager of large CI teams, Al has seen, been involved in and led hundreds of secondary and primary CI research projects, competitive simulations and strategic formulation projects. Al was also co-chair for the Pharma CI conference in the US and EU from 2017 to 2019.

Previously, Al was Executive Director and Head of Strategic Business Intelligence at Merck & Co. based in its US corporate headquarters. In this role, Al oversaw a broad portfolio of intelligence service offerings covering several therapeutic areas, corporate strategy, mergers and acquisitions, business development and licensing. In this capacity, he guided the drafting of the basic research strategy for Immuno-Oncology and support of Keytruda, contributed to the commercial launch and counter-launch strategies for brands and Merck’s Biosimilars business, and was one of few selected to inform the drafting of Merck’s 2025 corporate strategy. During his tenure, Al also led several of Merck & Co.’s special strategy projects that were successful in identifying targets for acquisitions and partnering.

Al earned his B.S. and M.S. in Microbiology and his PhD in Cell and Structural Biology at the University of Illinois, Urbana-Champaign. His research included papillomaviruses (M.S.) and cell adhesion through the integrin receptors (Ph.D.). He conducted postdoctoral research at the University of Washington, Seattle, with a focus on the interaction between the Mitogen-Activated Protein Kinases (ERKs 1 and 2) and the microtubule cytoskeleton. His earlier research as part of the Merck Research Laboratories focused on the elucidation of the mechanism of action of the nitrogen-containing bisphosphonates with a focus on alendronate, which is the active pharmaceutical ingredient of Fosamax.

Alfred is based in our Manhattan, NYC, East Coast office.

Peter Kelly, PhD joined Lifescience Dynamics in 2019 as an Engagement Manager. Peter brings diverse experience from finance, business, strategy, relationship and project management and scientific training to help his clients achieve success.

Prior to joining Lifescience Dynamics, Peter worked in financial services at the Bank of England. At the Bank, Peter led teams responsible for the supervision of several large and complex financial services companies, including the insurance firm AIG and investment bank Deutsche Bank. As a senior manager, he evaluated the business models and balance sheets of financial services firms, analysed and scrutinised whether management was appropriately identifying and managing risks to its business, and then created and implemented proactive solutions. This required in-depth understanding of banking and insurance product profiles, corporate strategy, competitive landscape, financial metrics, forecasting models, systems of risk management and governance, capital and liquidity. He also represented the Bank at international conferences and worked in partnership with EU and US regulatory agencies. During his time at the Bank, he was recognised as a subject matter expert in several areas, including financial risk modelling and effective governance of international financial groups.

Before working at the Bank of England, Peter worked as Senior Researcher for the UK Medical Research Council’s Clinical Sciences Centre, where he was part of the Nitric Oxide Signalling Group in the lab of Professor James M. Leiper, PhD.

Peter earned his B.A. in Molecular and Cellular Biology at the University of California at Berkeley, and later completed a PhD in Biochemistry from University College London School of Medicine. His thesis research focused on the role of endogenous nitric oxide synthase inhibitors in the modulation of immune and cardiovascular signalling. Peter also worked at the bench in research labs at Stanford University Medical School, the Memorial Sloan-Kettering Cancer Center and Imperial College London. His works are published in a wide range of peer-reviewed scientific journals.

Peter is based in our San Francisco, West Coast office.